PD-L1 inhibitor versus PD-1 inhibitor plus bevacizumab with transvascular intervention in unresectable hepatocellular carcinoma
Clinical and Experimental Medicine · 2024
DOI: 10.1007/s10238-024-01415-y ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical and Experimental Medicine, 2024. Verfasst von Zhenkun Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guan…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Bevacizumab, Liver Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province, Basic and Applied Basic Research Foundation of Guangdong Province, Science and Technology Projects in Guangzhou.
Abstract (Originalsprache)
Both atezolizumab (a PD-L1 inhibitor) plus bevacizumab (A+B) and sintilimab (a PD-1 inhibitor) plus bevacizumab (S+B) are recommended as the first-line regimen for advanced hepatocellular carcinoma (HCC) in China. Different efficacy between the two regimens combined with transvascular intervention for unresectable HCC (uHCC) remain unknown. We retrospectively analyzed uHCC patients treated in three centers by simultaneous combination of A+B or S+B with transarterial chemoembolization (TACE) and FOLFOX-based hepatic arterial infusion chemotherapy (HAIC). Objective response rate (ORR), progression-free survival (PFS), overall survival (OS) and treatment-related adverse events (TRAEs) were compared. Totally 188 patients were included, with 92 and 96 administered A+B+TACE-HAIC (ABTH) and S+B+TACE-HAIC (SBTH), respectively. ORRs (62.0 vs. 70.8%, respectively; P = 0.257) and disease control rates (88.0 vs. 93.8%, P = 0.267) were similar between groups by the mRECIST criteria. ABTH showed no survival advantage over SBTH, with median PFS times of 11.7 months and 13.0 months, respectively (HR = 0.81, 95% CI, 0.52–1.26, P = 0.35) and similar OS times (HR = 1.19, 95% CI, 0.32–4.39, P = 0.8). No significant differences were observed in grade 3–4 TRAEs between groups. Either PD-L1 or PD-1 inhibitor plus bevacizumab combined with TACE-HAIC have similarly excellent therapeutic efficacy with manageable adverse events, representing promising treatment options for uHCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China.
- Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China.
- Department of Hepatobiliary Surgery, The Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China.
- Department of Biliopancreatic Surgery, Sun Yat-Sen Memorial Hospital, Guangzhou, China.
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China. hewei@sysucc.org.cn.
- Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China. hewei@sysucc.org.cn.
Förderung
- Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province
- Basic and Applied Basic Research Foundation of Guangdong Province
- Science and Technology Projects in Guangzhou
Zitieren
APA
Huang, Z., Chen, T., Li, W., Qiu, J., Liu, S., Wu, Z., Li, B., Yuan, Y., & He, W. (2024). PD-L1 inhibitor versus PD-1 inhibitor plus bevacizumab with transvascular intervention in unresectable hepatocellular carcinoma. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-024-01415-y
Vancouver
Huang Z, Chen T, Li W, Qiu J, Liu S, Wu Z, et al. PD-L1 inhibitor versus PD-1 inhibitor plus bevacizumab with transvascular intervention in unresectable hepatocellular carcinoma. Clinical and Experimental Medicine. 2024. doi:10.1007/s10238-024-01415-y
BibTeX
@article{Huang2024,
author = {Huang, Zhenkun and Chen, Tiejun and Li, Wenbin and Qiu, Jiliang and Liu, Shaoru and Wu, Zongfeng and Li, Binkui and Yuan, Yunfei and He, Wei},
title = {PD-L1 inhibitor versus PD-1 inhibitor plus bevacizumab with transvascular intervention in unresectable hepatocellular carcinoma},
journal = {Clinical and Experimental Medicine},
year = {2024},
doi = {10.1007/s10238-024-01415-y}
}
EUVIMED